Carbon Nanotube Sponge Captures Circulating Tumor Cells Without Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating circulating tumor cells (CTCs) from blood are inefficient and require large blood samples or specific biomarkers, limiting their effectiveness and applicability.
Innovation Solution
A carbon nanotube (CNT) sponge is used to capture CTCs without the need for biomarkers, leveraging its structural and mechanical similarity to natural extracellular matrices to bind CTCs from small blood samples, allowing for efficient capture and viability of captured cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunomagnetic selection devices are used to capture CTCs, then specific tumor cell recognition is improved, but the required blood volume increases to at least 7.5 ml
Solution Approach 1:
The patent employs a porous carbon nanotube sponge material with high surface area and porous structure to capture CTCs. The sponge's three-dimensional network provides extensive contact area for cell adhesion, enabling efficient CTC capture from small blood volumes (≤2 ml) without requiring immunomagnetic reagents
Solution Approach 2:
The carbon nanotube sponge utilizes its inherent adhesive properties and structural characteristics to capture CTCs autonomously, without requiring external tumor-specific biomarkers or immunomagnetic agents. The material's natural affinity for tumor cells enables self-directed capture functionality
2Ease of operation
If physical properties-based techniques are used to isolate CTCs, then operation simplicity is improved, but accuracy deteriorates due to overlapping physical properties between CTCs and leukocytes
Solution Approach 1:
The carbon nanotube sponge provides differentiated local capture zones where tumor cells preferentially adhere due to their specific biological properties (adhesive characteristics, surface receptors), while leukocytes pass through or do not bind. This creates local selectivity at the material-cell interface without requiring complex separation procedures
3Measurement precision
If nano-engineered devices with adhesive molecules are used to capture CTCs, then capture specificity is improved, but operation cost and device complexity increase
Solution Approach 1:
The patent extracts and eliminates the requirement for complex immunomagnetic reagents, antibodies, and biomarker-specific agents from the CTC capture system. The carbon nanotube sponge alone provides sufficient capture capability, removing the need for additional molecular recognition components and simplifying the overall device architecture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CNT sponge effectively captures a significant percentage of CTCs from a small volume of blood, maintaining cell viability for further analysis, thus enabling early detection of metastatic diseases without the need for biomarker-specific agents.
Implementation Method 1
carbon nanomaterials such as carbon nanotubes and graphene have also been employed to assist in the capture of CTCs
Data Source
AI summary
The present invention provides a method of capturing circulating tumor cells (CTCs) from a subject without using a cancer biomarker. The method comprises contacting a test sample with a carbon nanotube (CNT) sponge. The test sample comprises cells from a small amount of peripheral blood from a subject after removal of plasma and lysis of erythrocytes. The cells in the test sample comprise CTCs from the subject. The CNT sponge is free of an agent specific for a cancer biomarker.